Haleon Faces Slow Q1 Due to Weak Flu Season, But Expects Improvement Later in Year

Haleon PLC's Q1 sales are expected to show subdued growth due to a weak cough and cold season in Europe and North America. Analysts forecast organic sales growth of around 2.2%, below consensus, with pricing remaining supportive. However, growth is expected to improve in the second half, driven by a US shelf reset and easing seasonal comparisons. Haleon's exposure to raw material cost inflation is relatively limited, and it has not been disrupted by geopolitical tensions in the Middle East.